
Long-term sargramostim led to motor gains for 5 patients
Long-term treatment with sargramostim, an immune-modulating medication from Partner Therapeutics, was safe and improved motor function for five men with Parkinson’s disease, according to data from a small open-label Phase 1 clinical trial. Evidence suggested the therapy exerted its benefits by boosting the function of anti-inflammatory…